• Complement Ther Med · Jun 2010

    Randomized Controlled Trial

    Effectiveness of subcutaneous injections of a cartilage preparation in osteoarthritis of the knee--a randomized, placebo controlled phase II study.

    • Roman Huber, Ute Prestel, Isabel Bloss, Ulrich Meyer, and Rainer Lüdtke.
    • Department of Environmental Health Sciences, University Hospital Freiburg, Breisacher Str. 115b, D-79106 Freiburg, Germany. roman.huber@uniklinik-freiburg.de
    • Complement Ther Med. 2010 Jun 1; 18 (3-4): 113-8.

    Objectives And MethodsArticulatio Genus D5 (AG5), a cartilage preparation, is widely used within anthroposophic medicine to treat osteoarthritis of the knee (OA). To evaluate its efficacy 91 OA patients were randomized to receive either AG5 (46) or placebo (45) following a fully sequential study design. For a period of 4 weeks AG5 or placebo were injected subcutaneously 3 times a week in the predominantly affected knee. Outcome parameters were the Western Ontario and Mc. Masters University Arthritis Index (WOMAC) scores and the use of concomitant pain medication during a follow up period of 2 months.Results89 patients completed the study. After 4 weeks of treatment WOMAC pain scores were significantly reduced compared to baseline (mean from 5.1+/-1.8 to 3.2+/-2.2 with AG5 and from 4.3+/-1.5 to 3.0+/-1.8 with placebo, p<0.001) in both groups. This effect was maintained until follow up (mean 3.3+/-2.6 with AG5 and 3.2+/-2.4 with placebo). WOMAC function- and stiffness scores and use of concomitant pain medication were also significantly reduced. There was, however, no significant difference between AG5 and placebo (group difference after 4 weeks: -3.3, CI: -11.8 to 5.3, p=0.46, triangular test). After follow up, WOMAC scores were also not different between AG5 and placebo but the use of pain medication dropped significantly more in the AG5 group (p=0.036). Severe side effects did not occur, minor side effects in 2 patients (1 in each group) were related to the subcutaneous injection.ConclusionsFor the primary outcome parameter pain AG5 was not superior to placebo after 4 weeks of treatment but the equal reduction of pain in combination with higher reduction of pain medication suggests an effect of the preparation. The long term effect of AG5 on sparing pain medication should be further investigated.Copyright 2010 Elsevier Ltd. All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.